Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

of NKTR-118 as a Selective Oral Peripheral Opioid Antagonist"

Poster #28: "NKTR-118 (oral PEG-naloxol), a PEGylated Derivative of Naloxone; Demonstration of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models"

Nektar PEGylation Platform

Nektar PEGylation technology can enhance the properties of therapeutic agents by increasing drug circulation time in the bloodstream, decreasing immunogenicity and dosing frequency, increasing bioavailability and improving drug solubility and stability. It can also be used to modify pharmaceutical agents to preferentially target certain systems within the body. It is a technique in which non-toxic polyethylene glycol (PEG) polymers are attached to therapeutic agents, and it is applicable to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs.

Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar is also developing its own product candidates by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding the potential of the company's PEGylation technology platform and NKTR-118. These forward-looking statements involve important risks and uncertainties, includ
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
(Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
(Date:9/1/2014)... September 01, 2014 As well as ... Derek is currently pursuing counselor certification in Louisiana. ... through the CPI training program as well as the ... have grown both personally and professionally. I am ... am competently able to do so. As a ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ... status conference in September, where issues related to claims ... Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... on the Court’s website, the meeting is scheduled to ... This is the latest of several Tylenol conferences that ...
(Date:9/1/2014)... 01, 2014 The Outlier Series announced ... exclusive interview content from one of the exceptional women ... Outliers: Women Game Changers . The title of the ... Game Changer Jenny McClendon . McClendon is currently a ... formerly the star of WeTV show, Raising Sextuplets. , ...
(Date:9/1/2014)... September 01, 2014 Psychogenic Non-epileptic Seizures ... a psychological disorder that can have devastating effects on ... like epileptic seizures however, they are not produced by ... triggers. It is estimated that the numbers of ... by multiple sclerosis. , Dr. Lorna Myers, ...
Breaking Medicine News(10 mins):Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2
... molecular mechanisms associated with the development and progression of ... The research, published by Cell Press in the January ... may lead to development of future strategies for treatment ... are derived from migratory neural crest cells that give ...
... January 5, 2008 Scientists from the Gladstone ... discovered that a certain type of collagen, collagen VI, ... widely thought to cause Alzheimer,s disease (AD). While the ... established, before this study it was unknown that collagen ...
... Oral-B Partner with Operation Smile to See the Difference, ... From January through March 2009, Crest and Oral-B are encouraging people ... own smile while also making a difference in children,s smiles worldwide. ... see the difference in their smile. People can also ...
... of infamous psychological obedience study in 1960s , , MONDAY, ... as willing to follow orders to hurt others as they ... , In a replication of one of the most famous ... give what they believed were increasingly painful electric shocks to ...
... Disability healthcare reform will be the subject of ... Disability (NCD) on Tuesday, January 13, 2009, from 3:00 ... held at the Chaparral Suites Resort, 5001 N. Scottsdale ... public. The forum will explore the relationship between health ...
... retinal cell gets infected with the common cytomegalovirus, contiguous ... may provide clues to better treatment of this potentially ... provide new insight into the larger issue of how ... a disease process such as diabetes, said Dr. Sally ...
Cached Medicine News:Health News:New insight into aggressive childhood cancer 2Health News:Collagen VI may help protect the brain against Alzheimer's disease 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 4Health News:Researcher Finds Most Will Inflict Pain on Others If Prodded 2Health News:Researcher Finds Most Will Inflict Pain on Others If Prodded 3Health News:Disability Healthcare Policy Forum to Be Held in Scottsdale, Arizona 2Health News:Cell death from cytomegalovirus may bring new life to treatment of retinal disease 2
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: